Tebentafusp for Uveal Melanoma: Adverse Events

Source: OncLive, August 2021

Marlana M. Orloff, MD: When I first started introducing the mechanism of tebe [tebentafusp], I mentioned that gp100 [glycoprotein 100] is in 2 places—on the tumor and in the skin on the melanoma site. There was another interesting abstract that talked about actually coprimary end point of rash with basically overall survival. What did you think about it?

READ THE ORIGINAL FULL ARTICLE